Cisplatin nephropathy
WebSide effect and toxicity management Prophylaxis and treatment Prevention and management of cisplatin nephrotoxicity ID: 184 v.3 Endorsed This document is an … WebCisplatin is a platinum containing drug first approved as an antineoplastic agent in 1978. It remains an important and effective therapy in many forms of cancer today. Cisplatin …
Cisplatin nephropathy
Did you know?
WebA large and growing number of studies have shown that patients with chronic kidney disease are less likely to undergo coronary angiography and revascularization than patients who do not have... WebAug 14, 2024 · Nephrotoxicity associated with cisplatin administration is common and unwanted adverse effect which has significantly restricted its clinical use [ 1 ]. Both acute and chronic nephrotoxicities associated with cisplatin tend to occur more frequently at higher doses or especially after repeated administration [ 2 ].
WebDec 21, 2024 · Previous publications have revealed that NOX4 overexpression exacerbated tubular damages in diabetic nephropathy , ischemia/reperfusion- or cisplatin-induced AKI [37,39], obstructive nephropathy , and hypertensive nephropathy . Thus, NOX4 can be up-regulated in various scenarios, which might be dependent upon its transcriptional or post ... WebJul 22, 2024 · It is important to note that for many malignancies, cisplatin is used in combination with other drugs that may also be nephrotoxic. Cellular toxicity — Cisplatin (cis-diamminedichloroplatinum II [CDDP]), a platinum compound that is predominantly …
WebJan 1, 1996 · CsA nephropathy was introduced as a PRD in the ERA-EDTA Registry in 1985 and, despite its rarity, is of particular interest as a new iatrogenic entity resulting from CsA administration, mainly in solid organ transplantation. In 1985, two new patients commenced RRT in Europe, and the number increased to 59 in 1991–93. WebMay 1, 2008 · Cisplatin is one of the most widely used and most potent chemotherapy drugs. However, side effects in normal tissues and organs, notably nephrotoxicity leading to tubular and inflammation. Renoprotective approaches are being discovered, but the protective effects are mostly partial, suggesting the need for combinatorial strategies.
WebOct 1, 2024 · We identified Compound-6c(Cpd-6c) as having the best activity and examined its protective effect against cisplatin nephropathy both in vivo and in vitro in cisplatin-stimulated tubular epithelial cells (TECs). Our results showed that Cpd-6c restored renal function more effectively than Ru, as evidenced by reduced blood urea nitrogen and …
WebNov 26, 2024 · Cisplatin is one of the commonly used anticancer drugs in clinic chemotherapy, but drug resistance is a major therapeutic obstacle for successful treatment. While ginkgolic C17:1 alone induced autophagy and apoptosis in the human hepatoblastoma cells HepG2, it was found to paradoxically inhibit cisplatin-induced … how to spell notifiedWebFeb 2, 2024 · 5.1 Cisplatin-Induced Nephrotoxicity. Cisplatin, ... Let us pay attention to whether, the body affected by nephropathy also causes further nephrotoxicity by breaking the balanced relationship between the two pathways, in addition to nephrotoxicity caused by the crosstalk of Nrf2 and NF-κB. When exploring whether diabetes aggravates I/R … rds case studyWebJul 7, 2007 · Despite the clinical effectiveness of cisplatin as an anti-tumour drug, its nephrotoxic side effect has significantly restricted its use. In spite of prophylactic … rds cdnWebDiabetic nephropathy is characterized by inflammation, fibrosis, and oxidant stress, pathologic features that are shared by many other … how to spell noticeablyWebCisplatin-nephropathy model mice exhibited elevated levels of serum IS accompanied by elevated levels of blood urea nitrogen and serum creatinine. Furthermore, intraperitoneal administration of IS in mice promoted tumor growth and metastasis. Finally, we found that the MasR agonist Ang-(1-7) suppressed the IS-mediated effects on cell ... rds car parkWebCisplatin ATN AKI, hypomagnesemia, renal sodium Chronic interstitial fibrosis and cyst formation wasting, CKD Ifosfamide ATN Fanconi syndrome (partial or complete) AKI ESRD Methotrexate Crystal nephropathy Nonoliguric AKI Pemetrexed ATN AKI AIN CKD Tubular atrophy and interstitial fibrosis Nephrogenic diabetes insipidus Ipilimumab AIN AKI rds center ltdWebwww.karger.com how to spell notifier